Moviendo las Caderas: Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors.
Our primary objective is to assess the feasibility, acceptability and explore the impact of a culturally appropriate LD intervention vs. UC on sleep quality for Hispanic cancer survivors.
Secondary objectives are to examine the preliminary efficacy of a culturally appropriate LD intervention on secondary cancer- and treatment-related side effects (e.g., QOL, distress, insomnia, fatigue).
- Rutgers University
Inclusion Criteria: - Be 18 years of age or older - Self-identify as Hispanic and/or Latino(a) - Have a confirmed diagnosis of a solid tumor or hematologic malignancy - Must have completed primary cancer treatment 3+ months prior to enrollment (e.g., chemotherapy, surgery, and/or radiation therapy but may be on hormonal therapy and/or immunotherapy or other long-term therapies) - Have sleep disturbance (indicated by a response of 3 or more on the MD Anderson Symptom Inventory sleep question by using an 11-point scale anchored by 0 [no sleep disturbance] and 10 [worst possible sleep disturbance] - Be able to read and understand English and/or Spanish - Physically Inactive (<150 minutes of vigorous exercise/week within the past 3 months) Exclusion Criteria: - Current regular Latin dancing practice within the past year (2-3 times a week over a period of two months that is not interrupted). - Inability to speak and read English or Spanish proficiently - Inability to understand informed consent - Medical conditions that can cause sleep impairment: sleep apnea, restless leg syndrome, shift work - Regular use of a walker or wheelchair - Healing or unhealed fractures - Heart failure - Life expectancy <12 months - Unwilling to be randomized to study arms and/or commit to 8 weeks of classes and a follow-up assessment
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.